MDA passes on J lead advice to UK doctors:
This article was originally published in Clinica
Executive Summary
The UK device regulator has recommended that patients implanted with Telectronics' Accufix atrial J pacemaker leads should now consider leaving them in place. The Medical Devices Agency (MDA) gave this advice to UK surgeons managing patients with the faulty leads based on advice from the Accufix Research Institute. The institute, set up in the wake of the Telectronics J lead adverse incidents in 1994, suggested in a "dear doctor" letter in November that surgeons should consider the age of the patient when considering a potentially life-threatening procedure to remove the leads. The J leads were taken off the market after lead fracture, with protrusion of the retention wire.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip